Cibus (CBUS) Reports Q3 2026 Results with Improved Net Loss and Strategic Shift to Direct-Sales Model

Cibus, Inc. (CBUS) reported third-quarter 2026 financial results characterized by a narrowing net loss of $21.9 million, an improvement from the $24.3 million lost in the prior year period. While quarterly revenue remained modest at $0.8 million—primarily driven by collaboration agreements—the company saw a 35% year-over-year increase in nine-month revenue to $3.5 million due to new research funding and its sustainable ingredients program. The company is undergoing a strategic pivot toward a direct-sales model for its biofragrance business, which management estimates could reach $100 million in peak annual revenue with high gross margins. To preserve liquidity, Cibus has implemented significant cost-saving measures, including laboratory consolidation and workforce reductions, reducing total operating expenses to $13.3 million. However, the company noted it expects to need additional capital in the near term as its current cash runway extends only into early Q1 2027.

5 articles from 2 sources · updated

Coverage